Are all β-blockers the same for chronic heart failure?

Current Cardiology Reports

Volumn 3, Issue 2, 2001, Pages 124-129

  Gottlieb, Stephen S ^a  

^a UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; HUMAN; MORTALITY; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 0035292615     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-001-0038-5     Document Type: Article

References (33)

1. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
2. Hjalmarson Å, Goldstein S, Fagerberg B, et al.: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000, 283:1295-1302.
3. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999, 353:9-13.
4. Packer M, Bristow MR, Cohn JN, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996, 334:1349-1355.
5. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I: Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979, 1:1374-1376.
6. Maack C, Cremers B, Flesch M, et al.: Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br J Pharmacol 2000, 130:1131-1139.
7. Newton GE, Parker JD: Acute effects of b1-selective and nonselective b-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation 1996, 94:353-358.
8. Talwar KK, Bhargava B, Upasani PT: Hemodynamic predictors of early intolerance and long-term effects of propranolol in dilated cardiomyopathy. J Card Fail 1996, 2:273-277.
9. Communal C, Singh K, Sawyer DB, Colucci WS: Opposing effects of b1- and b2-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis-toxin sensitive G protein. Circulation 2000, 100:2210-2212.
10. Keith M, Geranmayegan A, Sole MJ, et al.: Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998, 31:1352-1356.
11. Yue TL, Cheng HY, Lysko PG, et al.: Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992, 263:92-98.
12. Intengan HD, Schiffrin EL: Disparate effects of carvedilol versus metoprolol treatment of stroke-prone spontaneously hypertensive rats on endothelial function of resistance arteries. J Cardiovasc Pharmacol 2000, 35:763-768.
13. Flesch M, Maack C, Cremers B, et al.: Effect of beta-blockers on free radical-induced cardiac contractile dysfunction. Circulation 1999, 100:346-353.
14. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL: Beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000, 101:2103-2109.
15. Yue TL, Ma XL, Wang X, et al.: Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/ reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res 1998, 82:166-174.
16. Kukin ML, Kalman J, Charney RH, et al.: Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999, 99:2645-2651.
17. Cohn JN, Archibald DG, Ziesche S, et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986, 314:1547-1552.
18. ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone: the antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000, 283:1967-1985.
19. Australia-New Zealand Heart Failure Research Collaborative Group: Effects of carvedilol, a vasodilator-b-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995, 92:212-218.
20. Johnsson G, Svedmyr N, Thiringer G: Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics. Eur J Clin Pharmacol 1975, 8:175-180.
21. Lundborg P, Abrahamsson B, Wieselgren I, Walter M: The pharmacokinetics and pharmacodynamics of metoprolol after conventional and controlled-release administration in combination with hydrochlorothiazide in healthy volunteers. Eur J Clin Pharmacol 1993, 45:161-163.
22. Bristow MR, Gilbert EM, Abraham WT: Carvedilol produces dose-related improvements in left ventricular function survival in subjects with chronic heart failure. Circulation 1996, 94:2807-2816.
23. Wei S, Chow LTC, Sanderson JE: Effect of carvedilol in comparison with metoprolol on myocardial collagen infarction. J Am Coll Cardiol 2000, 36:276-281.
24. Gilbert EM, Abraham WT, Olsen S, et al.: Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996, 94:2817-2825.
25. Sanderson JE, Chan SKW, Yip G, et al.: Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999, 34:1522-1528.
26. Cintron G, Johnson G, Francis G, et al.: Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure: The V-HeFT VA Cooperative Studies Group. Circulation 1993, 87:VI17-VI23.
27. Metra M, Giubbini R, Nodari S, et al.: Differential effects of b-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000, 102:546-551.
28. Yusuf S, Wittes J, Friedman L: Overview of results of randomized clinical trials in heart disease. JAMA 1988, 260:2088-2093.
29. Heidenreich PA, Lee TT, Massie BM: Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997, 30:27-34.
30. Doughty RN, Rodgers A, Sharpe N, et al.: Effects of betablocker therapy on mortality in patients with heart failure: a systematic overview of randomised controlled trials. Eur Heart J 1997, 18:560-565.
31. Lechat P, Packer M, Chalon S, et al.: Clinical effects of beta-adrenergic blockade in chronic heart failure. Circulation 1998, 98:1184-1191.
32. Bonet S, Agustí A, Arnau JM, et al.: Beta-adrenergic blocking agents in heart failure. Benefits of vasodilating and nonvasodilating agents according to patients' characteristics: a meta-analysis of clinical trials. Arch Intern Med 2000, 160:621-629.
33. Yusuf S: Challenges in the conduct and interpretation of phase II (pilot) randomized trials. Am Heart J 2000, 139:S136-S142.